<DOC>
	<DOCNO>NCT00463073</DOCNO>
	<brief_summary>Irinotecan demonstrate activity malignant glioma multiple phase II study . The activity limit , approximately 15 % response rate progression-free survival 3-5 month . Given synergy irinotecan bevacizumab colorectal cancer , high-level expression vascular endothelial growth factor malignant glioma , one would expect synergy bevacizumab irinotecan glioma . In addition , 40-50 % GBM EGFR amplification/mutation make EGFR additional target . By comb cetuximab , irinotecan bevacizumab , one would expect response , irinotecan bevacizumab alone . In addition , recurrent glioma extremely poor prognosis , innovative therapy need .</brief_summary>
	<brief_title>Cetuximab , Bevacizumab Irinotecan Patients With Malignant Glioblastomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Written inform consent Histological verification primary GBM Recurrence progression standard treatment ( debulking surgery possible , radiotherapy temozolamide within last six month ) Evidence measurable recurrent progressive primary GBM ( CT/MRI scan ) PS 02 ( ECOG scale ) Age &gt; 18 Life expectancy &gt; 3 month Normal organ function : Platelets &gt; 125 x 109/l Hemoglobin &gt; 6,2 mmol/l Leukocytes &gt; 3 x 109/l ACN &gt; 1,5 x 109/l ASAT and/or ALAT &lt; 3 x upper normal limit Bilirubin &lt; 1,5 x upper normal limit Creatinine clearance &gt; 45 ml/min Creatinine &lt; 1,5 x upper normal limit APTT &lt; normal limit INR &lt; normal limit Cholesterol &lt; 7 mmol/l Fertile female must use oral contraceptive , IUD ( intrauterine device ) preservatives . Fertile male must use preservative . Exclusion criterion : Radiotherapy chemotherapy within last 4 week . Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid Prior EGFR VEGFR base therapy . Any condition ( medical , social , psychological ) , would prevent adequate information followup Any active malignancy previous malignancy within last 5 year , except , adequately treat basal squamous cell carcinoma skin , carcinoma situ . No hypercholesterolemia hypertriglyceridemia ( despite lipidlowering therapy ) . Any significant cardiac disease ( New York Heart Association Class II great ) , arrhythmia , congestive heart failure , acute myocardial infarction within 6 month unstable angina pectoris . Clinically significant peripheral vascular disease Evidence bleeding diathesis , coagulapathy take ASA , NSAIDs clopidogrel Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day 0 , anticipation need major surgical procedure curse study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior day 0 History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month prior day 0 History know HIV , Hepatitis B Hepatitis C negative Any ongoing infection , uncontrolled diabetes mellitus , serious nonhealing wound , ulcer bone fracture Pregnancy breast feeding Requires therapeutic anticoagulation Blood pressure &gt; 150/100 mmHG Grade 2 great proteinuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Progressive primary Glioblastoma multiforme</keyword>
</DOC>